

Prevention NOW!

November 2021 - Issue 73

World AIDS Day Message



This year's World AIDS Day theme, "Ending the HIV Epidemic: Equitable Access, Everyone's Voice," is a reminder that despite advances in prevention and treatment of HIV, access to HIV testing, treatment, and prevention tools remains a challenge we must address.

The HPTN's commitment to pursuing new HIV prevention tools and novel approaches to enhancing prevention effectiveness is anchored in the goal of providing all individuals at risk, regardless of race, ethnicity, gender identity, sexuality, class, or disability, access to the prevention strategies that fit their needs. Our commitment is to ensure HIV prevention is integrated with ways to prevent sexually transmitted infections and unintended pregnancies.

We are grateful to our Network members and partners, research teams, funders, community organizations, other stakeholders, and most of all, our study participants that have supported our ongoing research aimed at ending the HIV global epidemic.

Thank you all for your continued hard work, dedication, and passion.

Dr. Myron S. Cohen HPTN Principal Investigator Dr. Wafaa M. El-Sadr HPTN Principal Investigator

Shoutouts



Dr. Allysha C. Maragh-Bass



Dr. Typhanye V. Dyer

Two HPTN Scholars recently participated in a panel discussion at the 2021 International Conference on Stigma entitled "Ending the Epidemic for Who: Considerations for Uplifting Youth Voices." Dr. Allysha C. Maragh-Bass, a 2018-2019 Domestic Scholar, is a scientist at FHI 360, an adjunct professor at Duke Global Health Institute in Durham, N.C., and a visiting professor at UC San Francisco. Dr. Typhanye V. Dyer, a 2011-2012 Domestic Scholar, is an associate professor in the Department of Epidemiology and Biostatistics at the University of Maryland School of Public Health.



HPTN 084 protocol co-chair Dr. Mina Hosseinipour recently completed the Tour of Karamoja, Uganda's ultimate wilderness bicycle tradition, biking nearly 500 kilometers. She was recognized as the 'youngest rider' and 'strongest female cyclist.' Dr. David Serwadda, HPTN Executive Committee member, joined the second half of the Tour, biking nearly 200 kilometers and using the event to raise money for young girls' education in Karamoja. He took up cycling during the COVID-19 global epidemic. Dr. Hosseinipour reports both she and Dr. Serwadda discussed HIV prevention during evening campfires.

Network Member Spotlight

Dr. Hyman Scott, HTPN 083 protocol team member and co-investigator for HPTN 091 at Bridge HIV in San Francisco, is the clinical research medical director at Bridge HIV and an assistant clinical professor of Medicine at the University of California, San Francisco. His research focuses on implementing HIV prevention and COVID-19 vaccine clinical trials, using technology to expand HIV/STI testing and PrEP, and addressing racial/ethnic disparities in HIV incidence. Dr. Scott is also an HIV and PrEP provider at the Positive Health Program (Ward 86). In addition, he leads PrEP implementation within the San Francisco Department of Health primary care clinics and serves as medical director for the San Francisco AIDS Foundation Strut Clinic.



What aspect of your role do you enjoy the most?

I most enjoy the ability to work with volunteers and community members who are committed to helping us find new HIV prevention tools. Their altruism and willingness to donate time and undergo procedures to advance HIV prevention science provide daily inspiration.

Read More

Hot Off The Press

Leddy AM, Selin A, Lippman SA, Kimaru LJ, Twine R, Gómez-Olivé X, Kahn K, Pettifor A. <u>Emotional Violence is Associated with Increased HIV Risk Behavior Among South African Adolescent Girls and Young Women in the HPTN 068 Cohort.</u> AIDS Behav. 2021 Nov 20.

Marzinke MA, Grinsztejn B, Fogel JM, Piwowar-Manning E, Li M, Weng L, McCauley M, Cummings V, Ahmed S, Haines CD, Bushman LR, Petropoulos C, Persaud D, Adeyeye A, Kofron R, Rinehart A, St Clair M, Rooney JF, Pryluka D, Coelho L, Gaur A, Middelkoop K, Phanuphak N, Cohen MS, Hendrix CW, Anderson P, Hanscom B, Donnell D, Landovitz RJ, Eshleman SH. Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083. J Infect Dis. 2021 Nov 16;224(9):1581-1592.

Brown TT, Yuhas K, Mayer KH, Landovitz RJ, Marzinke MA, Hendrix CW, Chen YQ, Klingman KL, Chege W, Mccauley MB, Gulick RM, Wilkin TJ. <u>Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.</u> J Antimicrob Chemother. 2021 Nov 13:dkab400.

Bell-Mandla NF, Sloot R, Maarman G, Griffith S, Moore A, Floyd S, Hayes R, Fidler S, Ayles H, Bock P; HPTN 071 (PopART) study team. <u>Improving retention of community-recruited participants in HIV prevention research through Saturday household visits: findings from the HPTN 071 (PopART) study in South Africa.</u> BMC Med Res Methodol. 2021 Nov 8;21(1):242.

Sugarman J, Donnell DJ, Hanscom B, McCauley M, Grinsztejn B, Landovitz RJ. <u>Ethical issues in establishing the efficacy and safety of long-acting injectable pre-exposure prophylaxis for HIV prevention: the HPTN 083 trial.</u> Lancet HIV. 2021 Nov;8(11):e723-e728.

Stoner MCD, Edwards JK, Westreich D, Kilburn K, Ahern J, Lippman SA, Gómez-Olivé FX, Kahn K, Pettifor A. Modeling Cash Plus Other Psychosocial and Structural Interventions to Prevent HIV Among Adolescent Girls and Young Women in South Africa (HPTN 068). AIDS Behav. 2021 Nov;25(Suppl 2):133-143.

Maragh-Bass AC, Gamble T, El-Sadr WM, Hanscom B, Tolley EE. <u>Exploring individual-level barriers to HIV medication adherence among men who have sex with men in the HIV Prevention Trials Network (HPTN 065) study.</u> AIDS Care. 2021 Nov;33(11):1404-1413.

Viljoen L, Hoddinott G, Malunga S, Vanqa N, Mhlakwaphalwa T, Marthinus A, Mcimeli K, Bond V, Seeley J, Bock P, Hayes R, Reynolds L; HPTN 071 (PopART) study team. Women's sexual scripting in the context of universal access to antiretroviral treatment-findings from the HPTN 071 (PopART) trial in South Africa. BMC Women's Health. 2021 Oct 24;21(1):370.





